SOURCE: Radient Pharmaceuticals

Radient Pharmaceuticals

October 04, 2011 07:00 ET

Radient Pharmaceuticals Launches U.S. National Marketing Campaign for Onko-Sure® Colorectal Cancer Test

Retains Firm Led by Top Marketing & Advertising Executives

TUSTIN, CA--(Marketwire - Oct 4, 2011) - Radient Pharmaceuticals Corporation "the Company" or "Radient" (OTCQX: RXPC) (PINKSHEETS: RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced the launch of a national marketing campaign to drive awareness and adoption of Onko-Sure® for its FDA cleared indication in treatment monitoring and recurrence monitoring of colorectal cancer. This comprehensive campaign includes online and print marketing, advertising, and public relations aimed at key constituencies including doctors, patients, and labs. The campaign will support three new sales people hired by Radient for domestic U.S. sales. Radient will look to expand its sales channels as the national marketing campaign progresses.

Radient's national marketing campaign currently involves a redesign and launch of a new Onko-Sure® website, mobile apps, online and social media marketing. Future planned phases will include print and online advertising in high-impact medical and scientific publications. These actions will be coordinated with product awareness efforts through public relations and patient advocacy groups.

To support its marketing and sales strategy, Radient has retained the services and expertise of two key executives, Chad Meisinger and Bill Quinn, via their newly launched venture, Over The Top, an internet marketing firm.

Chad Meisinger, Founder of Over The Top, is a former Google executive, internet entrepreneur and business owner who has been on the leading edge of internet marketing for almost two decades. He is recognized as a top player in the internet evolution. Chad's experience includes everything from start-ups to being a key executive and principal at dMarc, a high-tech communications firm that eventually sold for $1.2 billion to industry giant Google. Chad was then hired by Google to manage sales and marketing for Google's Radio Ads program for three years, gaining unique insights into the intricacies of world-class search engines, their criteria for ranking success, and the opportunities they offer for driving qualified customers to all types of businesses.

Bill Quinn, Senior Advertising and PR Consultant for Over The Top, is a former advertising and public relations agency owner and marketing consultant with over 40 years of industry experience. He founded, built and sold two successful advertising agencies and has served as VP of Marketing and PR at several high-tech California companies. Bill has worked with companies of all sizes, from start-ups to Fortune 500 companies, including companies like Nicolet Biomedical, one of the world's leading manufacturers of neurophysiological diagnostic and monitoring instrumentation used in medical clinics, doctors' offices and testing laboratories on 5 continents. Bill helped launch as many as six new Nicolet Biomedical products a year. Over the years, Bill has also worked as an outside marketing consultant with well known companies like Google, Owens Illinois, Motorola, Best Western and Oscar Mayer Foods.

"Onko-Sure® is a high-value, cost effective cancer test that can really improve treatment outcomes for colorectal cancer patients. By launching this comprehensive national marketing campaign, we are making the key decision makers -- physicians, labs, and patients, aware of the importance of incorporating Onko-Sure® into colorectal cancer treatment plans," stated Radient Chairman and CEO Douglas MacLellan. "The fact that we have attracted Chad and Bill, two very accomplished and effective marketing and advertising executives, speaks volumes regarding our product and the opportunity we are pursuing to make a difference in cancer survival rates and improved quality of life."

For additional information on Radient Pharmaceuticals Corporation and its products visit: www.radient-pharma.com or e-mail info@radient-pharma.com. For Investor Relations contact Dilek Mir at: ir@radient-pharma.com or 714-881-0244.

The following table is intended to provide the latest information on Radient's business metrics:

RPC's Business Metrics
Cash on hand: $394,000*

*Approximate amount as of September 30, 2011
Common Shares Outstanding: 647 million*

*Approximate number as of September 30, 2011.

750 million shares authorized.
Outstanding Warrants & Options: 111 million*

*Approximate number as of September 30, 2011

Radient Pharmaceuticals:

Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com.

Forward-Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.